Daniel P. Bednarik, Ph.D. Joins BioHealth Innovation Commercial Relevance Advisory Board (CRAB).

Share Article

Daniel Bednarik, Biotechnology Professional and Cardiovascular/Infectious Disease expert joins BioHealth Innovation's Commercial Relevance Advisory Board (CRAB).

Daniel Bednarik, Biotechnology Professional and Cardiovascular/Infectious Disease expert joins BioHealth Innovation's Commercial Relevance Advisory Board (CRAB).

Dr. Bednarik was formerly Director of Genomics and Bioinformatics for Cardiome Pharma Corporation. He was previously co-founder and Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc., which was acquired by Cardiome in 2005. Dr. Bednarik served as a consultant for Cardiome for two years and was subsequently hired in 2007 to develop genomic and proteomic biomarker programs to help augment and accelerate clinical trial design. He created the largest known cardiovascular gene expression database for Gene Logic, which served as a prized source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics. Dr. Bednarik served as a key scientist for the development of Human Genome Sciences' (HGS) database and has over 28 years experience in the field of virology with emphasis on HIV and herpes virus pathology. He was recipient of a DARPA contract in 2006 where he and his colleagues developed a novel non-host method for rapid vaccine manufacture. His training was completed at Temple University School of Medicine (Philadelphia) in 1985, and The Johns Hopkins University Oncology Center (Baltimore).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daniel Bednarik
dbednarik@gmail.com
443-864-1445
Email >
Visit website